Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHua WangYLYu LiJZJie Zha

Discussion

Loading...

Member takes

Overview

Prospective clinical trial shows 81.8% overall response rate and promising safety in treatment-naïve marginal zone lymphoma patients, indicating potential for chemotherapy-free treatment options.

Key Points

  • Overall response rate reached 81.8% in treatment-naïve marginal zone lymphoma patients, showing significant efficacy.
  • Efficacy metrics include complete response rate of 72.7% and disease control rate of 81.8% with median follow-up of 5.5 months.
  • Assessment carried out in a prospective clinical trial setting, leveraging response rates calculated using confidence intervals.
  • Supports the potential of orelabrutinib and rituximab consolidation as a safe systemic therapy for MZL patients without effective local options.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da1ahttps://doi.org/10.1182/blood-2025-3580
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  2. 2Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  3. 3Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025
  4. 4Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)2025
  5. 5A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.2025